Company profile

HC Biopharma Inc.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
PD-1 / CTLA-4 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1
Undisclosed / early pipeline
Systemic Lupus Erythematosus

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.